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Interpretation of
erythropoietin levels in
patients with various degrees
of renal anemia
To the Editor: In interesting paper, Fehr et al [1] showed
relative erythropoietin deficiency in patients with GFR
<40 mL/min, and concluded that it was the sequence of
either altered set point for hormone production or due
to renal tissue damage. On the other hand, Machiguchi
et al’s paper [2] and our preliminary study led to ex-
tend Fehr’s explanation. Machiguchi et al [2] have shown
that in patients with IgA nephropathy and relatively pre-
served renal function (sCr 0.5-2.5 mg/dL), urinary excre-
tion of N-acetyl-b-D-glucosaminidase (NAG) inversely
correlated with serum erythropoietin concentration. Ac-
cording to these results, our recent study by Sulikowska
et al [3] showed that functional status of renal vascula-
ture, estimated as dopamine-induced glomerular filtra-
tion response (DIR), strongly correlated with NAG ex-
cretion. Furthermore, our preliminary study conducted
in 30 untreated IgA patients, with GFR 109 ± 27.5
mL/min, showed that DIR correlated with changes of
serum erythropoietin concentration during dopamine in-
fusion (serum erythropoietin, before dopamine mean:
10.9, range: from 1.3 to 10.4; after dopamine mean: 9.2,
range: from 1.8 to 29.1 U/L) and 24-hour proteinuria (r
= −48; P< 0.05), (r = 37; P< 0.05), respectively. In the
same study, dopamine-induced changes of serum erythro-
poietin correlated with both 24-hour urinary NAG ex-
cretion and proteinuria (r = 0.56; P< 0.02), (r = 0.43;
P< 0.03), respectively. Data from Machiguchi et al [2],
together with our finding, suggest that proteinuria is a
crucial factor disturbing the function of tubulointerstitial
compartment (tubules, vessels, and interstitial cells) as a
whole. Presented data, and comments of Fehr et al, sug-
gest that serum erythropoietin concentration come into
view as a marker of functional status of tubulointerstitial
compartment in patients with various degrees of renal
damage. Regarding these data, we have commenced the
study to examine whether serum erythropoietin could be
used as a marker to predict the progression of renal dis-
ease.
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Reply from the Authors
We would like to thank Sulikowska et al for their
comments to our study [1]. We were not aware of the
cited study performed in patients with IgA nephropa-
thy and moderate renal insufficiency, which showed that
urinary N-acetyl-b-D-glucosaminidase (NAG) excretion
inversely correlated with serum erythropoietin levels [2].
Together with their own data also obtained in patients
with IgA nephropathy, the authors suggest that serum
erythropoietin may be a marker for the functional sta-
tus of the tubulointerstitial compartment in patients with
various degrees of renal damage.
Although this hypothesis is intriguing and worth to pur-
sue further, there are “caveats.” First, NAG is commonly
used as a marker for tubular damage. Sulikowska et al
mention that NAG excretion in their patients positively
correlated with proteinuria, and that the latter may be re-
sponsible for tubular dysfunction, as described earlier [3].
However, in order to prove the tubular origin of NAG,
they should formally exclude the possibility of glomerular
filtration of NAG in the context of nonselective glomeru-
lar proteinuria. They would have to demonstrate the ab-
sence of immunoglobulins in the urine, which have about
the same molecular weight as NAG, and measure other
tubular markers (as a1-microglobulin).
Second, the findings in patients with IgA nephropathy
may not be generalizable for all patients with renal insuf-
ficiency. The same is true for our own findings, which were
obtained in a population with mainly diabetic, hyperten-
sive, and vascular renal disease. The well-known example
of polycystic kidney disease reminds us that the diagno-
sis of primary kidney disease may indeed play an impor-
tant role for the interpretation of erythropoietin levels. In
these patients, erythropoietin secretion is markedly pre-
served, despite advanced renal insufficiency, and some
of these patients may even remain independent of ery-
thropoietin while on dialysis [4]. Therefore, one should
look closely at the main trigger of erythropoietin secre-
tion in each of these diseases, namely, the partial pressure
of oxygen in the renal medulla.
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Opportunity and cost of
sevelamer in dialysis
patients
To the Editor: Manns et al [1] have recently pointed
out the high cost of replacing by sevelamer, the calcic
phosphate-binder, and the higher prevalence of patients
who would necessitate sevelamer according to K/DOQI
guidelines in America than in Canada, and in hemodialy-
sis patients (66% vs. 54%) than in peritoneal dialysis pa-
tients (60% vs. 38% in U.S. and Canadian patients, respec-
tively). These differences suggest us that it may be due to
higher prevalence of 1 a OH vitamin D use and, more pre-
cisely, of intravenous Calcijex or Zemplar in the U.S.
because of the Medicare reimbursement policy, with only
drugs given during the dialysis session being reimbursed.
Indeed, the Teng Cohort Study [2] pointed out than within
a year, the prevalence of hypercalcemia increased from
6.7% to 8.2%, and that of hyperphosphatemia increased
from 11.9% to 13.9%. This suggests, therefore, that to de-
crease the cost of Ca-phosphate-binder replacement by
sevelamer, the first measure to take would be to prevent
vitamin D insufficiency (thanks to an S 25 OH vitamin
D ≥30 ng/mL as recommended in the K/DOQI), and to
decrease the use of 1 a OH vitamin D mainly by system-
atically not using a dialysate calcium of 1.25 mmol/L, a
concentration known for 31 years to stimulate PTH secre-
tion [3], but rather, using the 1.5 mmol/L concentration
recommended by Argiles [4].
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Economic impact of sevelamer
in patients with ESRD
To the Editor: We read with interest the excellent and
timely article by Manns et al on the economic impact
of the use of sevelamer in ESRD patients [1]. Unfor-
tunately, the authors were unable to include the Cal-
cium Acetate Renagel Evaluation (CARE) study in their
pharmacoeconomics analysis because it was published af-
ter their cut-off date [2]. Likewise, results of the CARE
study were not available during the development of the
current K/DOQI clinical practice guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease
[3].
Given the enormous financial burden of caring for the
ever-increasing dialysis population, it is imperative that
two criteria be met before expanding Medicare benefits to
cover the cost of sevelamer: (1) sevelamer must be shown
to be at least as effective as calcium acetate in achieving
K/DOQI guidelines for serum phosphorus and Ca × P
product; and (2) sevelamer should have documented ben-
eficial effects on the rates of hospitalization and mortality.
Unfortunately, sevelamer has not been shown to meet ei-
ther of these two criteria. In the CARE study, calcium
acetate was clearly more efficacious than sevelamer as a
phosphate binder [2]. Because uncontrolled hyperphos-
phatemia is associated with a number of clinical conse-
quences [4], use of more effective phosphate binders may,
in fact, be associated with lower overall health care cost.
Finally, because the alleged link between calcium load-
ing from use of calcium-based phosphate binders and
cardiovascular calcification has not been substantiated
in well-designed controlled trials, the argument for the
